2021 at a glance

766 m

Patients reached

with Novartis medicines

21

Major approvals (US, EU, Japan, China)

including two new molecular entity approvals from the US Food and Drug Administration (FDA)

3

Breakthrough therapy designations

from the FDA

51.6 bn

Net sales

growing 4% in constant currencies from 2020 (USD)

16.6 bn

Core operating income

growing 6% in constant currencies from 2020 (USD)

7.4 bn

Total dividends paid 

to shareholders (USD)

71 bn

Treatments supplied

through Novartis facilities

78

Employee engagement

score in Q4 (out of 100), 5 points higher than the industry benchmark

300 000

Patients using AI Nurse

our cardiovascular disease app in China

1 bn

Antimalarial treatments

delivered in the past two decades in endemic countries, more than 90% of which were supplied without profit

40 m

Doses produced

of the Pfizer-BioNTech vaccine for COVID-19

-34%

Greenhouse gas emissions

reduced vs. 2016 baseline (Scope 1 and Scope 2)